What’s Exciting in Translational Cancer Research, According to Katie Sloan, Investor at Cancer Research Horizons.
Cancer survival rates in the UK have doubled over the past 50 years due to advancements in early diagnosis and treatment, with Cancer Research UK (CRUK) playing a key role by funding nearly £400 million in research annually. In an interview with Katie Sloan, an investment manager at Cancer Research Horizons, we highlight CRH's efforts in accelerating oncology innovation, including supporting early-stage ventures like Trogenix, which is developing a novel gene therapy platform targeting aggressive cancers such as glioblastoma, with promising preclinical results and planned clinical trials in 2025.
Lucy Ahern
April 3, 2025